Devonian Health Group Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Andre Boulet
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 360, rue des Entrepreneurs Québec QC Canada G5V 4T1
- IPO Date
- Sep 19, 2022
- Website
- groupedevonian.com
- Similar Companies
- Business
- Devonian Health Group Inc. is a Canadian clinical-stage pharmaceutical company specializing in the development of botanical prescription drugs for autoimmune inflammatory diseases, including gastrointestinal, dermatological, and hepatologic conditions. The company offers Thykamine, its lead product candidate from the SUPREX platform in phase 3 clinical trials for atopic dermatitis in adults, phase 2/3 trials for pediatric atopic dermatitis, phase 2 trials for hand-foot syndrome associated with chemotherapy and radiodermatitis linked to radiotherapy, and phase 2a trials for ulcerative colitis; high-value cosmeceutical products such as R-Spinasome and Purgenesis; and operates Altius Healthcare Group LP, a subsidiary distributing licensed prescription pharmaceuticals in Canada. Devonian conducts operations from its state-of-the-art extraction facility in Quebec with full traceability from seed to pill, targeting unmet medical needs supported by U.S. FDA guidelines favoring botanical drug pathways. Founded in 2015 and headquartered in Quebec, Canada, with listings on TSXV: GSD and OTCQB: DVHGF, the company recently filed new patent applications in February 2025 for Thykamine's use as an antifibrotic agent and in treating metabolic dysfunction-associated steatohepatitis, reported positive in vivo results on fibrosis-related gene expression, reinstated TSXV quotation in April 2025 following a cease trade order resolution, appointed new officers and granted stock options in June 2025, and achieved 275% year-over-year revenue growth in Q2 2025 alongside full debt repayment.
Devonian Reports Results of its Annual General and Special Meeting of Shareholders
Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026
Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
Devonian Advances Thykamine™ Patent Strategy with Proprietary Fingerprint and Robust Manufacturing Controls
Devonian reports additional molecular data from MASH liver study
DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
DEVONIAN APPOINTS DENNIS TURPIN AS CHIEF FINANCIAL OFFICER AND PROVIDES UPDATES ON STOCK OPTIONS GRANT
DEVONIAN ANNOUNCES SHARE CONSOLIDATION IN FURTHER PREPARATION FOR POTENTIAL U.S. LISTING
Devonian Health Group Announces Grant of Stock Options
Devonian Health Group Announces Publication of Landmark Study Highlighting Thykamine™ as a Promising New Anti-Inflammatory Agent
Devonian Health Group Reports its Fourth Quarter and Annual 2025 Financial Results and Appointment of a New Board Member
Devonian Health Group Inc. announces its participation to the ThinkEquity Conference in New York and closing of a Non-Brokered Private Placement of Units
Devonian Provides Corporate Update and Additional Information Regarding its Previously Announced Private Placement
Devonian Announces Closing of a Private Placement of Units
Devonian Health Group Reports Third Quarter 2025 Financial Results
Devonian Appoints New Officers and Announces Grant of Stock Options
Devonian Health Group Announces Reinstatement of Quotation on the TSXV
Devonian Health Group Reports Cease Trade Order
Devonian Reports Delay of Financial Reporting
Devonian Reports Results of its Annual General and Special Meeting of Shareholders